Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group.
BACKGROUND
MST-16, a new orally administered bis(2,6-dioxopiperazine) analogue and an inhibitor of topoisomerase II, was given to 24 patients with adult T-cell leukemia-lymphoma (ATLL) in a Phase I-II multi-institutional cooperative study.


METHODS
MST-16 was administered orally daily for 7 days, with courses repeated at intervals of 2-3 weeks in 24 patients.


RESULTS
Two complete remissions (CR) and eight partial remissions (PR) were obtained in 23 evaluable patients who received 1200-2800 mg/day of MST-16. Among 13 acute-type ATLL, one CR and five PR were obtained. Among eight lymphoma-type ATLL, two PR were detected. Among two chronic-type ATLL, one CR and one PR occurred. Remissions were obtained at 7-232 days (median, 23 days) and lasted 43-374 days (median, 68 days). The major toxic effects were leukopenia (68%), anemia (52%), thrombocytopenia (35%), and gastrointestinal disorders (22%).


CONCLUSIONS
MST-16 was shown to be effective in ATLL, which has no standard therapy. This drug deserves further clinical trials because it shows little cross resistance to currently available antitumor drugs.
Department of Medicine, Nagoya University School of Medicine, Japan.
R
R
Ohno
T
T
Masaoka
S
S
Shirakawa
S
S
Sakamoto
M
M
Hirano
S
S
Hanada
K
K
Yasunaga
S
S
Yokomaku
Y
Y
Mitomo
K
K
Nagai
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002415:Cats; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D010879:Piperazines; D059005:Topoisomerase II Inhibitors; C057773:sobuzoxane